The Vaccine Group completes two deadly disease vaccination projects

Digital Asset Direct by Frontier IP Group PLC

London, UK | December 07, 2022 08:24 AM Eastern Standard Time

Frontier IP Group PLC (AIM:FIPP, OTC:FGPPF) portfolio company The Vaccine Group (TVG) CEO Jeremy Salt speaks to Proactive after announcing that TVG has recently completed vaccine projects both for Streptococcus suis and for Lassa fever. Salt reveals a remarkable feature of the Lassa fever vaccine and looks ahead to what investors can expect from TVG during the coming year.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Why News Direct

For Public Relations For Investor Relations Testimonials

About us Features News Hub

Resources

Press Blog

Why News Direct For Public Relations For Investor Relations Testimonials

What We Offer Collaborative Content Studio Advanced News Release Capability Standalone Multimedia Distribution Industry-Leading Security Unsurpassed Global Reach Actionable Analytics Synergistic PR Solutions

Pricing About us News Hub

Resources Blog Press